Apolipoprotein concentrations during treatment and recurrent coronary artery disease events

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 20, Issue 11, 2000, Pages 2408-2413

  Van Lennep, Jeanine E Roeters ^a   Westerveld, H Tineke ^b   Van Lennep, Henk W O Roeters ^c   Zwinderman, Aelko H ^a   Erkelens, D Willem ^b   Van Der Wall, Ernst E ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c Oosterschelde Hospital   (Netherlands)

Author keywords

Apolipoproteins; Coronary disease; Lipids; Risk factors

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RECURRENT DISEASE; RISK ASSESSMENT;

EID: 0033764375     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.20.11.2408     Document Type: Article

References (34)

1. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
2. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study
3. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study
4. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
5. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators
6. New perspectives on the management of low levels of high-density lipoprotein cholesterol
7. Hypertriglyceridemia as a cardiovascular risk factor
8. Apolipoprotein B and coronary artery disease in women: A cross-sectional study in women undergoing their first coronary angiography
9. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular study
10. Comparison of the plasma levels of apolipoproteins B and A-1, and other risk factors in men and women with premature coronary artery disease
11. National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
12. Comparison of patients with <60% to > or=60% diameter narrowing of the myocardial infarct-related artery after thrombolysis. The TIMI Investigators
13. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
14. Current Perspectives on Statins
15. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)
16. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT)
17. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial
18. Cholesterol reduction and clinical benefit. Are there limits to our expectations?
19. Beyond LDL cholesterol reduction
20. Lipoprotein metabolism
21. Measurement of apoproteins: Time to improve the diagnosis and treatment of the atherogenic dyslipoproteinemias
22. Evidence for a new pathophysiological mechanism for coronary artery disease regression: Hepatic lipase-mediated changes in LDL density
23. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study
24. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)
25. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: The follow-up study of the Lipid Research Clinics Prevalence Study
26. High-density lipoprotein cholesterol and coronary, cardiovascular and all cause mortality among middle-aged Norwegian men and women
27. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies
28. IdentifiCation of scavenger receptor SR-BI as a high density lipoprotein receptor
29. Long-term predictors of subsequent cardiovascular events with coronary artery disease and 'desirable' levels of plasma total cholesterol
30. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group
31. The role of lipoprotein A-I and lipoprotein A-I/A-II in predicting coronary artery disease
32. Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease
33. Metabolism of high density lipoprotein subfractions
34. Cause of death in clinical research: Time for a reassessment?